The authorization is predicated on outcomes from the part III research KEYNOTE-B96, also referred to as ENGOT-ov65. Credit score: Asian Remoted/Shutterstock.com. Merck (MSD) has acquired European Fee (EC) approval for Keytruda (pembrolizumab) along with paclitaxel, with or with out bevacizumab, as a remedy for programmed loss of life ligand 1 (PD-L1)-positive ovarian most cancers. The approval within the European Union […]